SynaptixBio_BACKGROUND_dark2.png

Business digest C&I Issue 11, 2021

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodystrophy, a disease of the central nervous system. The company has entered into a research agreement with Children’s Hospital of Philadelphia (CHOP) in the US related to a new method for treating the disease and has an option to licence CHOP research related to this project.


To continue reading please go to the article on SCI






39 views0 comments

Recent Posts

See All

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr